Pharmaceutical Composition Containing Prostaglandin

Abstract

An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F 2α in a preparation containing prostaglandin F 2α . The object was attained by formulating a prostaglandin F 2α derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid triglyceride, a water-soluble polymer and water.

1 . A pharmaceutical composition comprising an oil-in-water emulsion containing a prostaglandin F 2α  derivative, an oil, a water-soluble polymer and water. 
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the prostaglandin F 2α  derivative is at least one member selected from latanoprost, isopropyl unoprostone, travoprost and bimatoprost. 
     
     
         3 . The pharmaceutical composition according to  claim 2 , wherein the prostaglandin F 2α  derivative is latanoprost. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein the water-soluble polymer is at least one member selected from a polyvinyl compound, a water-soluble cellulose compound and a polysaccharide. 
     
     
         5 . The pharmaceutical composition according to  claim 4 , wherein the polyvinyl compound is polyvinyl alcohol. 
     
     
         6 . The pharmaceutical composition according to  claim 1 , wherein the oil is an animal or vegetable oil, and/or medium chain fatty acid triglyceride. 
     
     
         7 . The pharmaceutical composition according to  claim 6 , wherein the medium chain fatty acid triglyceride is Miglyol. 
     
     
         8 . The pharmaceutical composition according to any one of  claims 1  to  7 , wherein the pharmaceutical composition is an opthalmological composition. 
     
     
         9 . The pharmaceutical composition according to  claim 8 , wherein the opthalmological composition is an eye drop. 
     
     
         10 . An eye drop which is an oil-in-water emulsion, comprising latanoprost, Miglyol, polyvinyl alcohol and water. 
     
     
         11 . A method of suppressing degradation of a prostaglandin F 2α  derivative in an emulsion, comprising blending a prostaglandin F 2α  derivative, an oil, a water-soluble polymer and water to form an oil-in-water emulsion. 
     
     
         12 . A method of suppressing degradation of latanoprost in an emulsion, comprising blending latanoprost, Miglyol, polyvinyl alcohol and water to form an oil-in-water emulsion.